These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31106377)

  • 1. Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial.
    Groeneveld GH; van der Reyden TJ; Joosten SA; Bootsma HJ; Cobbaert CM; de Vries JJC; Kuijper EJ; van Dissel JT
    J Antimicrob Chemother; 2019 Aug; 74(8):2385-2393. PubMed ID: 31106377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.
    de Porto AP; Liu Z; de Beer R; Florquin S; de Boer OJ; Hendriks RW; van der Poll T; de Vos AF
    Mol Med; 2019 Jan; 25(1):3. PubMed ID: 30646846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in drug resistance in pneumococcal community-acquired pneumonia.
    Obando I; Arroyo L; Sanchez-Tatay D
    Chest; 2007 Jul; 132(1):359; author reply 359-60. PubMed ID: 17625101
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of beta-lactam agents in the treatment of community-acquired pneumonia.
    Garau J
    Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):83-99. PubMed ID: 15696306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course beta-lactam treatment for community-acquired pneumonia.
    Stralin K; Sjöberg L; Holmberg H
    Clin Infect Dis; 2004 Mar; 38(5):766-7. PubMed ID: 14986269
    [No Abstract]   [Full Text] [Related]  

  • 8. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.
    Bordon JM; Fernandez-Botran R; Wiemken TL; Peyrani P; Uriarte SM; Arnold FW; Rodriquez-Hernandez L; Rane MJ; Kelley RR; Binford LE; Uppatla S; Cavallazzi R; Blasi F; Aliberti S; Restrepo MI; Fazeli S; Mathur A; Rahmani M; Ayesu K; Ramirez J
    Infection; 2015 Dec; 43(6):729-38. PubMed ID: 26424683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
    Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia.
    Mufson MA; Stanek RJ
    Clin Infect Dis; 2006 Jan; 42(2):304-6. PubMed ID: 16355349
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review.
    Falagas ME; Siempos II; Bliziotis IA; Panos GZ
    Mayo Clin Proc; 2006 Dec; 81(12):1567-74. PubMed ID: 17165635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia.
    Naucler P; Darenberg J; Morfeldt E; Ortqvist A; Henriques Normark B
    Thorax; 2013 Jun; 68(6):571-9. PubMed ID: 23442364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
    Piso RJ; Arnold C; Bassetti S
    Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased?
    Vallès X; Marcos A; Pinart M; Piñer R; Marco F; Mensa JM; Torres A
    Chest; 2006 Sep; 130(3):800-6. PubMed ID: 16963678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
    Mills GD; Oehley MR; Arrol B
    BMJ; 2005 Feb; 330(7489):456. PubMed ID: 15684024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefuroxime for empiric treatment of community-acquired pneumococcal pneumonia: is there a generation gap?
    Wiener-Well Y; Raveh D; Schlesinger Y; Yinnon AM; Rudensky B
    Chemotherapy; 2009; 55(2):97-104. PubMed ID: 19145079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.